uploads///Chart

MedMen’s Territory Expansion: The Recent Agreements

By

Dec. 4 2020, Updated 10:53 a.m. ET

MedMen’s agreements

MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.

The above chart lists a few of the company’s recent agreements. They are subject to regulatory approval and certain closing conditions, and there’s no assurance of their completion. Including these acquisitions, MedMen’s business includes licenses for 69 retail stores and 17 cultivation and production facilities in 12 states.

Article continues below advertisement

Level Up, Arizona

MedMen entered into a definitive acquisition agreement with Kannaboost Technology and CSI Solutions, called Level Up, on November 1. Level Up includes two Arizona-based vertically integrated operations, including retail locations in Scottsdale and Tempe, and cultivation and production facilities in Tempe and Phoenix. MedMen also received a 40% stake in the brand K.I.N.D. Concentrates.

Buddy’s, San Jose

MedMen entered into a definitive acquisition agreement with Buddy’s, with cultivation and production operations, on October 22. This licensed dispensary is a two-story building in San Jose.

Article continues below advertisement

B12 LLC, San Francisco Bay Area

MedMen entered into a definitive acquisition agreement with B12 to acquire a licensed dispensary in Emeryville, California, just outside San Francisco, on October 10.

Seven Point, Illinois

MedMen entered into a definitive acquisition agreement with Seven Point, a licensed medical cannabis dispensary in Oak Park, Illinois, on October 3.

Monarch, Arizona

MedMen entered into a definitive acquisition agreement with WhiteStar Solutions to acquire Monarch, based in Scottsdale, Arizona, on October 2. MedMen is also to acquire WhiteStar’s co-manufacturing and licensing agreements with Kiva, Huxton, and Mirth Provisions for Arizona.

The ETFMG Alternative Harvest ETF (MJ) invests 8.6% of its total portfolio in Tilray (TLRY), 7.3% in Aurora Cannabis (ACB), and 1.5% in Cara Therapeutics (CARA)

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.